A handful of small caps, including Sensei and PDS, jumped on Asco abstract data, with much more news to come.
After years of waiting, courtesy of Allogene investors at last have an allogeneic Car-T dataset comparable with autologous therapies.
Impower-010 scores on an apparently approvable endpoint, but the effect in all-comers is illusory, researchers reckon.
The registrational Spearhead-1 trial of afami-cel backs up the efficacy seen in phase 1, without some of the related toxicities.
The Relativity-047 study shows that relatlimab has a big safety advantage over Yervoy, with just a slight decrease in clinical benefit.
The IPF drug shows surprising promise in heart failure with preserved ejection fraction.
But does it hit hard enough?
Results in a handful of patients raise hopes again for Curis's blood cancer project CA-4948, but it is still early days.
If imminent results of Sanofi’s amcenestrant in Ameera-3 are positive Serds could finally see late-stage validation.